RS

Rohit Shivlagan Giri

Active Director Additional Director DIN 10628226
DIN 10628226 First appointment May 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Rohit Shivlagan Giri

Data last updated:

Rohit Shivlagan Giri is an Additional Director at Oreck Pharma Private Limited (since 2024). The company operates in Pharma.

DIN 10628226
Primary Designation Additional Director
Industry Pharma
First Appointment 15 May 2024
Oldest Company Age 8 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Oreck Pharma Private Limited U51909MH2017PTC301357
Additional Director15 May 20242017Active

Board colleagues of Rohit Shivlagan Giri

NameDINCompanyDesignation
Shri Krishna Yadav10628167Oreck Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Oreck Pharma Private Limited
Premium access

Shareholding and investment profile for Rohit Shivlagan Giri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rohit Shivlagan Giri

Rohit Shivlagan Giri currently holds 1 directorship: Oreck Pharma Private Limited (Additional Director, since 15 May 2024).

Rohit Shivlagan Giri was first appointed on 15 May 2024 as Additional Director at Oreck Pharma Private Limited.

The current boards of Rohit Shivlagan Giri's companies include Shri Krishna Yadav (Oreck Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available